<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00618657</url>
  </required_header>
  <id_info>
    <org_study_id>UCI 07-61 [HS# 2007-6084]</org_study_id>
    <secondary_id>2007-6084</secondary_id>
    <secondary_id>NCI-2010-00155</secondary_id>
    <secondary_id>R01CA127927</secondary_id>
    <nct_id>NCT00618657</nct_id>
  </id_info>
  <brief_title>Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting</brief_title>
  <official_title>A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II is studying the side effects and how well carboplatin and paclitaxel&#xD;
      albumin-stabilized nanoparticle formulation when together with bevacizumab or trastuzumab&#xD;
      before surgery works in treating patients with stage I-III breast cancer. Drugs used in&#xD;
      chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Monoclonal antibodies, such as bevacizumab and trastuzumab, can&#xD;
      block tumor growth in different ways. Some block the ability of tumor cells to grow and&#xD;
      spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.&#xD;
      Giving more than one drug (combination chemotherapy) and monoclonal antibody therapy together&#xD;
      before surgery may make the tumor smaller and reduce the amount of normal tissue that needs&#xD;
      to be removed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate 2 year progression-free survival in patients with breast cancer more than 1 cm&#xD;
      and/or lymph node positive breast cancer treated with weekly Carboplatin/Nab-Paclitaxel (with&#xD;
      trastuzumab in patients with HER2+ disease, and with bevacizumab in HER2-).&#xD;
&#xD;
      II. To measure clinical response rates in patients treated in the neoadjuvant setting.&#xD;
&#xD;
      III. To measure the microscopic pathological response rate of this regimen in patients&#xD;
      treated in the neoadjuvant setting.&#xD;
&#xD;
      IV. To measure the toxicity and delivered dose intensity of this regimen. V. To assess the&#xD;
      association between microscopic pathologic complete response and clinical complete response&#xD;
      at the primary tumor site in these patients.&#xD;
&#xD;
      VI. To measure the outcome of patients treated with doxorubicin and cyclophosphamide with&#xD;
      patients not treated with doxorubicin and cyclophosphamide.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Develop quantitative analysis methods to obtain pre-treatment tumor characteristic&#xD;
      morphological, enhancement kinetic, and Choline metabolic parameters in breast cancer. Select&#xD;
      an optimal set of features using the logistic regression analysis and the Artificial Neural&#xD;
      Network (ANN) to predict pathologic complete remission (pCR) in HER-2 positive and negative&#xD;
      arm.&#xD;
&#xD;
      II. Investigate whether the early response patterns, analyzed using the percent tumor size&#xD;
      changes, or changes in other lesion characteristic parameters, can be used to predict&#xD;
      pathologic complete remission (pCR) in HER-2 positive and negative arm.&#xD;
&#xD;
      III. Investigate whether combining the pre-treatment tumor characteristic parameters, and the&#xD;
      early response pattern during the treatment course, can achieve a higher &quot;area under the&#xD;
      receiver operating characteristic (ROC) curve&quot; (AUC) in prediction of pCR than those based on&#xD;
      pre-treatment MRI characteristics or tumor response patterns alone.&#xD;
&#xD;
      OUTLINE: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30&#xD;
      minutes and carboplatin IV over 60 minutes once weekly for 12 weeks. Patients with&#xD;
      HER2-positive disease receive trastuzumab IV over 30-90 minutes once weekly for 12 weeks and&#xD;
      patients with HER2-negative disease receive bevacizumab IV over 30-90 minutes once every two&#xD;
      weeks for 5 doses. Treatment continues in the absence of disease progression or unacceptable&#xD;
      toxicity. Beginning 21-40 days later, patients undergo surgery.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Progression is defined as a new lesion or a greater than or equal to 25% increase in the product of the largest perpendicular diameters of any one lesion on clinical exam or by ultrasound (U/S) or MRI. Analyzed using the Kaplan-Meier method. Cox proportional-hazards analysis will be used to derive the hazard ratio and 95% confidence interval between the two treatment arms, adjusted for clinical and demographic variables.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical complete response in the neoadjuvant setting</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Defined as normal breast on physical exam. No mass, no thickening, no erythema, no peau d'orange. The 95% confidence interval (CI) will be computed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microscopic pCR in the neoadjuvant setting</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Defined as no evidence of microscopic invasive tumor at the primary tumor site in the surgical specimen. The 95% CI will be computed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of the combinations in HER2 positive and HER2 negative breast cancer assessed using the National Cancer Institute (NCI) Common Toxicity Criteria version 3.0</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The frequency of toxicities will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Breast Cancer</condition>
  <condition>HER2-negative Breast Cancer</condition>
  <condition>HER2-positive Breast Cancer</condition>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Stage IA Breast Cancer</condition>
  <condition>Stage IB Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (HER-2 positive)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes, carboplatin IV over 60 minutes, and trastuzumab IV over 90 minutes , then weekly over 30-60 minutes. Treatment repeats every week for 12 weeks in the absence of disease progression or unacceptable toxicity. In both arms, beginning 21-40 days later, patients undergo surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (HER-2 negative)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel albumin-stabilized nanoparticle formulation and carboplatin as in Arm I. Patients also receive bevacizumab IV over 90 or 60 or 30 minutes once every two weeks for 5 doses in the absence of disease progression or unacceptable toxicity. In both arms, beginning 21-40 days later, patients undergo surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (HER-2 positive)</arm_group_label>
    <arm_group_label>Arm II (HER-2 negative)</arm_group_label>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>CBDCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel albumin-stabilized nanoparticle formulation</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (HER-2 positive)</arm_group_label>
    <arm_group_label>Arm II (HER-2 negative)</arm_group_label>
    <other_name>Albumin-Stabilized Nanoparticle Paclitaxel</other_name>
    <other_name>nab paclitaxel</other_name>
    <other_name>nab-paclitaxel</other_name>
    <other_name>nanoparticle albumin-bound paclitaxel</other_name>
    <other_name>Nanoparticle Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (HER-2 negative)</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody</other_name>
    <other_name>anti-VEGF monoclonal antibody</other_name>
    <other_name>anti-VEGF rhuMAb</other_name>
    <other_name>recombinant humanized anti-VEGF monoclonal antibody</other_name>
    <other_name>rhuMAb VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (HER-2 positive)</arm_group_label>
    <other_name>anti-c-erB-2</other_name>
    <other_name>MOAB HER2</other_name>
    <other_name>monoclonal antibody c-erb-2</other_name>
    <other_name>monoclonal antibody HER2</other_name>
    <other_name>rhuMAb HER2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
    <description>Optional correlative studies</description>
    <arm_group_label>Arm I (HER-2 positive)</arm_group_label>
    <arm_group_label>Arm II (HER-2 negative)</arm_group_label>
    <other_name>MRI</other_name>
    <other_name>NMR imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>nuclear magnetic resonance imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Post-chemotherapy surgery for patients with a response or stable disease must take place no sooner than 21 days after last dose of Herceptin; and 40 days after last dose of bevacizumab to allow for normalization of blood counts</description>
    <arm_group_label>Arm I (HER-2 positive)</arm_group_label>
    <arm_group_label>Arm II (HER-2 negative)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Patients must be women with a histologically confirmed diagnosis of breast cancer that&#xD;
             is more than 1 cm and or lymph node positive&#xD;
&#xD;
          -  Physical examination, and scans needed for tumor assessment must be performed within&#xD;
             90 days prior to registration&#xD;
&#xD;
          -  Patients with the clinical diagnosis of congestive heart failure or angina pectoris&#xD;
             are NOT eligible&#xD;
&#xD;
          -  Serum creatinine within normal limits within 90 days prior to registration&#xD;
&#xD;
          -  Bilirubin within normal limits within 90 days prior to registration&#xD;
&#xD;
          -  Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate&#xD;
             transaminase (SGPT) =&lt; 2 x the institutional upper limit of normal within 90 days&#xD;
             prior to registration&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) of &gt;= 1,500/microliters within 90 days prior to&#xD;
             registration&#xD;
&#xD;
          -  Platelet count of &gt;= 100,000/microliters within 90 days prior to registration&#xD;
&#xD;
          -  Patients must have a performance status of 0-2 by Zubrod criteria&#xD;
&#xD;
          -  Pregnant or nursing women may not participate; women of reproductive potential may not&#xD;
             participate unless they have agreed to use an effective contraceptive method;&#xD;
             pregnancy test required for women of childbearing potential&#xD;
&#xD;
          -  In calculating days of tests and measurements, the day a test or measurement is done&#xD;
             is considered day 0; therefore, if a test is done on a Monday, the Monday four weeks&#xD;
             later would be considered day 28; this allows for efficient patient scheduling without&#xD;
             exceeding the guidelines; if day 28 or 42 falls on a weekend or holiday, the limit may&#xD;
             be extended to the next working day&#xD;
&#xD;
          -  All patients must be informed of the investigational nature of this study and must&#xD;
             sign and give written informed consent in accordance with institutional and federal&#xD;
             guidelines&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rita Mehta, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chao Family Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 7, 2008</study_first_submitted>
  <study_first_submitted_qc>February 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2008</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pre-operative</keyword>
  <keyword>neo-adjuvant</keyword>
  <keyword>triple negative</keyword>
  <keyword>HER2 positive</keyword>
  <keyword>hormone receptor positive</keyword>
  <keyword>breast</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Nab-paclitaxel</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Inflammatory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

